z-logo
Premium
Host genetic variations associated with disease progression in chronic hepatitis C virus infection
Author(s) -
Matsuura Kentaro,
Tanaka Yasuhito
Publication year - 2018
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.13042
Subject(s) - hepatocellular carcinoma , hepatitis c virus , medicine , genome wide association study , hepatitis c , immunology , disease , interferon , liver disease , virus , virology , genotype , single nucleotide polymorphism , gene , biology , genetics
Treatment with recently developed interferon‐free oral regimens combining direct‐acting antiviral agents (DAAs) results in the elimination of hepatitis C virus (HCV) in almost all chronic hepatitis C (CHC) patients. In the era of DAAs, surveillance of hepatocellular carcinoma (HCC) after eradication of HCV by anti‐HCV therapy is particularly important. As is well known, an advanced state of hepatic fibrosis is the major risk factor for developing HCC. Therefore, an increased understanding of various factors associated with disease progression and development of HCC in CHC patients is essential for implementing personalized treatment and surveillance of disease progression and HCC. Recent genome‐wide association studies (GWAS) have identified several host genetic variants influencing treatment efficacy or clinical course in HCV infection. This review focuses on these host genetic variations recently identified, mainly by GWAS, which are associated with the clinical course of chronic HCV infection, especially disease progression and hepatocarcinogenesis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here